Close menu




Bionxt Solutions Inc.

Photo credits: pixabay.com

Commented by André Will-Laudien on March 15th, 2023 | 17:38 CET

Bayer, BioNxt, BioNTech - Biotech is on the rise again, bring on the blockbusters!

  • Biotechnology
  • vaccine
  • Covid19

The time of the vaccine producers is over because the willingness to vaccinate is declining worldwide. As a result, the entire biotech sector has entered a strong correction phase since the pandemic mode for COVID-19 ended. In the process, sector leader BioNTech suffered a loss of over 70% from its high. Complicating matters for companies is the significant increase in interest rates for long-term financing of their pipelines. When refinancing costs rise, this often leads to lower valuations. However, some companies are impressing with their innovations and have recently shown significant outperformance to the market. We evaluate the opportunities of some well-known biotech protagonists!

Read

Commented by Fabian Lorenz on March 9th, 2023 | 10:52 CET

BioNTech, Pfizer, Bayer and BioNxt Solutions on the biotech takeover merry-go-round

  • Biotechnology
  • Pharma

2023 could become the year of takeovers in the pharmaceutical and biotech sectors. This is what the experts at PwC expect. Thus, at the JP Morgan industry conference in San Francisco, not only were takeover candidates discussed but billion-dollar transactions were reported. One reason is the Inflation Reduction Act in the USA. This allows negotiations on drug prices. To prevent sales declines, Big Pharma must invest in new top sellers. And it is already doing so. The latest takeover rumor comes from BioNTech partner Pfizer. At BioNTech, the negative news currently outweighs the positive. Whether Bayer will take action with the boss or be taken over itself is not yet entirely clear. But there are also opportunities for investors in the smallcap sector. Take BioNxt Solutions, for example - the Canadian company with its operational focus in Germany recently secured new patents, and the share price has jumped.

Read

Commented by Stefan Feulner on March 1st, 2023 | 14:01 CET

BioNTech, BioNxt Solutions, Bayer - Turn of the tide

  • Biotechnology
  • Covid19

Just how fundamental biotechnology already is for humanity was demonstrated by the development of the various COVID vaccines, which was extremely rapid by historical standards. Previously unknown companies such as BioNTech, Valneva and CureVac came into the focus of the stock market and were able to multiply within a very short time. Even after the pandemic has ended, research in the biotech sector is running at full speed. This is giving rise to new, innovative growth companies that could follow a similar trajectory in the future.

Read

Commented by Nico Popp on February 14th, 2023 | 15:49 CET

Takeover fever around biotechs - Bayer's reaction, purchase candidates BioNxt and Morphosys?

  • Biotechnology

Something is happening in the biotech sector: several global players are looking for potential acquisition targets. Above all, pharmaceutical companies focusing on the US are seeing their chances of survival dwindle in light of the Inflation Reduction Act. If drug prices are to fall, new products must be developed or costs cut elsewhere. We take a look at the industry and do a takeover check.

Read

Commented by Juliane Zielonka on December 23rd, 2022 | 08:00 CET

BioNxt Solutions, MorphoSys, BioNTech - Innovations and scaling potential for the portfolio

  • Biotechnology

Around the world, patients are used to swallowing medicines in pill form. Sales of oral, fixed-dose drugs alone accounted for a whopping 23.8% of the global pharmaceutical drug delivery market in 2021. That is reason enough for Canadian biotech company BioNxt Solutions to further expand its strategic pole position. BioNxt Solutions secures further rights to a unique platform technology in this segment. Caution is currently the order of the day for MorphoSys. Analysts downgrade the target price from EUR 16 to EUR 12 after a disappointing Q3. BioNTech, on the other hand, can expand its dominance. The Mainz-based company is scaling up in the Asia-Pacific region with new production sites.

Read

Commented by Stefan Feulner on December 8th, 2022 | 09:25 CET

Core One Labs, BioNxt Solutions, Moderna - Takeover battle in a billion-dollar market

  • Biotechnology

The sharp correction of recent months hit the capital-intensive biotech sector particularly hard. Shares, mainly from the second tier, have, in some cases, had to absorb losses of more than three-quarters of their market value and are trading far below their cash levels. These distortions naturally attract the big players to acquire novel developments at bargain prices.

Read

Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

  • Biotechnology
  • Cancer
  • Investments

Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

Read

Commented by Nico Popp on November 21st, 2022 | 12:11 CET

Biotech - Hotter than ever: Catalyst Pharmaceuticals, BioNxt Solutions, Bayer

  • Biotechnology

Biotechs have been providing answers to humanity's most pressing questions for years. Innovative companies are applying advanced methods to make a medical difference. The example of BioNTech is just one success story among many. While companies in the pharmaceutical sector are finding it increasingly difficult to come up with real innovations, biotechs often put all their eggs in one basket - and win. We present two biotech hopefuls and take a look at Bayer.

Read

Commented by Juliane Zielonka on November 17th, 2022 | 13:48 CET

BioNxt Solutions, Pfizer, Bayer - Biotech and pharma stocks in focus

  • Biotechnology
  • Investments

Pharma and biotech companies are still booming. However, large corporations like Pfizer and Bayer need help maintaining their market dominance with long-term studies and patent extensions. Pfizer, in particular, experienced the rush of speed in recent years thanks to the emergency approval of the Covid-19 vaccine. In hindsight, however, voices are growing louder about the potential long-term damage of this market cut. Multi-million dollar lawsuits may result. Positioning itself in the mental health niche, whose market size was USD 381.98 billion in 2020, is BioNxt Solutions. Their mission: to tackle depression, anxiety and PTSD with natural substances. A look at the data.

Read